Pitcairn Co. Takes $197,000 Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Pitcairn Co. bought a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 14,201 shares of the company’s stock, valued at approximately $197,000.

Other hedge funds have also recently bought and sold shares of the company. Bleakley Financial Group LLC grew its holdings in Takeda Pharmaceutical by 19.1% during the first quarter. Bleakley Financial Group LLC now owns 288,535 shares of the company’s stock worth $4,008,000 after acquiring an additional 46,182 shares during the period. XY Capital Ltd increased its stake in Takeda Pharmaceutical by 432.5% in the 4th quarter. XY Capital Ltd now owns 765,137 shares of the company’s stock worth $10,919,000 after purchasing an additional 621,440 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its stake in Takeda Pharmaceutical by 7.4% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 25,763 shares of the company’s stock worth $358,000 after purchasing an additional 1,778 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in Takeda Pharmaceutical by 0.7% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 130,904 shares of the company’s stock worth $1,818,000 after purchasing an additional 857 shares in the last quarter. Finally, OLD Mission Capital LLC increased its stake in Takeda Pharmaceutical by 1,440.9% in the 4th quarter. OLD Mission Capital LLC now owns 1,041,526 shares of the company’s stock worth $14,863,000 after purchasing an additional 973,935 shares in the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Trading Up 0.7 %

Shares of TAK opened at $13.67 on Friday. The business’s 50-day moving average price is $13.20 and its 200 day moving average price is $13.79. The stock has a market capitalization of $43.50 billion, a P/E ratio of 24.85, a P/E/G ratio of 0.41 and a beta of 0.54. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $16.39. The company has a current ratio of 1.11, a quick ratio of 0.58 and a debt-to-equity ratio of 0.62.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.